Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein.   

Reference is made to the stock exchange release from SoftOx Solutions AS (the
"Company") 2nd of September 2024 regarding the final result of the Subsequent
Offering and allocation of Offer shares.     

The new share capital following the completion of the Subsequent Offering has
today been registered with the Norwegian Register of Business Enterprises. 

The new share capital of the Company is NOK 35 085 558 divided into 1 754 277
900 shares, each with a par value of NOK 0,02. 


For any questions or interview requests, please contact:  

Geir Almås, Chair of SoftOx Solutions AS  

Mail: ir@soft-ox.com  

Phone: Geir Almås: (+47) 977 59 071  

About SoftOx Solutions AS  

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB (WIAB),
and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx
is developing a highly effective antimicrobial solution for use in biofilm,
viral, and antimicrobial-resistant infections. The patent-protected technology
is based on extensive research and development in partnership with leading
Nordic research institutes. 

For more information on SoftOx, visit www.soft-ox.com